Sharon Mates - 29 Aug 2024 Form 4 Insider Report for Intra-Cellular Therapies, Inc. (ITCI)

Role
Chairman and CEO, Director
Signature
/s/ John P. Condon, Attorney-in-fact
Issuer symbol
ITCI
Transactions as of
29 Aug 2024
Net transactions value
-$4,198,136
Form type
4
Filing time
30 Aug 2024, 18:01:46 UTC
Previous filing
28 Aug 2024
Next filing
06 Dec 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ITCI Common Stock Options Exercise $453,239 +35,604 +3.3% $12.73 1,105,933 29 Aug 2024 Direct
transaction ITCI Common Stock Sale $2,161,114 -29,832 -2.7% $72.44 1,076,101 29 Aug 2024 Direct F1, F2
transaction ITCI Common Stock Sale $422,771 -5,772 -0.54% $73.25 1,070,329 29 Aug 2024 Direct F1, F3
transaction ITCI Common Stock Options Exercise $437,861 +34,396 +3.2% $12.73 1,104,725 30 Aug 2024 Direct
transaction ITCI Common Stock Sale $2,051,261 -28,203 -2.6% $72.73 1,076,522 30 Aug 2024 Direct F1, F4
transaction ITCI Common Stock Sale $454,091 -6,193 -0.58% $73.32 1,070,329 30 Aug 2024 Direct F1, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ITCI Stock Option (right to buy) Options Exercise $0 -35,604 -21% $0.000000 137,093 29 Aug 2024 Common Stock 35,604 $12.73 Direct F6
transaction ITCI Stock Option (right to buy) Options Exercise $0 -34,396 -25% $0.000000 102,697 30 Aug 2024 Common Stock 34,396 $12.73 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2024.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.02 to $73.015, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.02 to $73.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.27 to $73.26, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.28 to $73.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F6 All shares underlying this option have vested.